Ayala Pharmaceuticals (NASDAQ:ADXS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report issued on Sunday morning. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Price Performance

Shares of ADXS stock opened at $0.03 on Friday. Ayala Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $1.49. The firm has a market capitalization of $1.15 million, a price-to-earnings ratio of 0.00 and a beta of 1.62. The business has a 50 day simple moving average of $0.03 and a 200 day simple moving average of $0.06.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.